Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala
Ingia / Ingia
The invention relates to .beta.-alanine derivatives of the formula I ##STR2##
in which Q.sub.1, Q.sub.2, Q.sub.3 or Q.sub.4 is, in each case, independently of one another, CH or N, R.sup.1 is H, A, Ar, Hal, OH, OA, CF.sub.3 or OCF.sub.3, R.sup.2 is H or A, ##STR3## R.sup.4 and R.sup.5 are, in each
Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala
Ingia / Ingia
BACKGROUND OF THE INVENTION
The present invention relates to novel substituted .beta.-alanine derivatives which are useful for the inhibition and prevention of leukocyte adhesion and leukocyte adhesion-mediated pathologies. This invention also relates to compositions containing such compounds and
Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala
Ingia / Ingia
BACKGROUND OF THE INVENTION
Field of the Invention
This invention relates to certain 3-(heteroaryl)alanine derivatives which inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4.
References
The following publications, patents and patent applications are cited in this
Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala
Ingia / Ingia
BACKGROUND OF THE INVENTION
Field of the Invention
This invention relates to certain 3-(heteroaryl)alanine derivatives which inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4.
REFERENCES
The following publications, patents and patent applications are cited in this
Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala
Ingia / Ingia
FIELD OF THE INVENTION
The present invention relates to peptides comprising lysine, alanine, leucine and valine, pharmaceutical compositions comprising same, and uses thereof for treating inflammatory conditions and allergy.
BACKGROUND OF THE INVENTION
Antimicrobial Peptides
Lipopolysaccharides
Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala
Ingia / Ingia
BACKGROUND OF THE INVENTION
Complement anaphylatoxin C5a is a 74-amino acid peptide generated from the fifth component of complement (C5) during complement activation (Ember et al., Immunopharmacology 38:3, 1997; Gerard, Annu Rev Immunol. 12:775, 1994). C5a acts efficiently as an anaphylatoxin
Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala
Ingia / Ingia
FIELD OF THE INVENTION
The present invention relates to peptides having anti-inflammatory properties. In particular, the present invention relates to peptides through actions on cells that modify the leukocyte recruitment and activation cascade and the actions of mediators released from inflammatory
Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala
Ingia / Ingia
This invention relates to a series of alkanoic acid derivatives, to processes for their preparation, and to their use in medicine.
Over the last few years it has become increasingly clear that the physical interaction of inflammatory leukocytes with each other and other cells of the body plays an
Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala
Ingia / Ingia
This invention relates to a series of bicyclic heteroaromatic alanine derivatives, to compositions containing them, to processes for their preparation, and to their use in medicine.
Over the last few years it has become increasingly clear that the physical interaction of inflammatory leukocytes with
Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala
Ingia / Ingia
CROSS-REFERENCE TO RELATED APPLICATION
This application is the U.S. national stage application of International Patent Application No. PCT/EP2003/051090, filed Dec. 22, 2003, the disclosure of which is hereby incorporated by reference in its entirety, including all figures, tables and amino acid or
Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala
Ingia / Ingia
FIELD OF THE INVENTION
The invention relates to an amino acid ester compound and to compositions comprising the amino acid ester compound. The invention also relates to use of the compound or composition in the inhibition of the p38 MAP kinase enzyme. In addition, the invention relates to an acid
Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala
Ingia / Ingia
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a national phase application under 35 U.S.C. .sctn.371 that claims priority to International Application No. PCT/GB2013/052689 filed Oct. 15, 2013, which claims the benefit of priority to Great Britain Patent Application Nos. 1306881.2
Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala
Ingia / Ingia
FIELD OF THE INVENTION
The invention relates to an amino acid ester compound and to compositions comprising the amino acid ester compound. The invention also relates to use of the compound or composition in the inhibition of the p38 MAP kinase enzyme. In addition, the invention relates to an acid
Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala
Ingia / Ingia
This Application claims the benefit of U.S. Provisional Application No. 60/714,512 filed May 5, 2004.
FIELD OF THE INVENTION
The present invention relates to IL-1 receptor antagonists and methods of modulating IL-1 receptors activity with same. More specifically, the present invention is concerned
Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala
Ingia / Ingia
BACKGROUND OF THE INVENTION
The present invention relates to cyclosporin derivatives, their production and their use for therapy.
The cyclosporins comprise a group of cyclic, poly-N-methylated undecapeptides having valuable therapeutic properties, particularly as immunosuppressive and
Hifadhidata kamili ya mimea ya dawa inayoungwa mkono na sayansi
Inafanya kazi katika lugha 55
Uponyaji wa mitishamba unaungwa mkono na sayansi
Kutambua mimea kwa picha
Ramani ya GPS inayoshirikiana
Soma machapisho ya kisayansi yanayohusiana na utafutaji wako
Tafuta mimea ya dawa na athari zao
Panga maslahi yako na fanya tarehe ya utafiti wa habari, majaribio ya kliniki na ruhusu
Andika dalili au ugonjwa na usome juu ya mimea ambayo inaweza kusaidia, chapa mimea na uone magonjwa na dalili ambazo hutumiwa dhidi yake. * Habari zote zinategemea utafiti wa kisayansi uliochapishwa